GlobeNewswire (Nov 9, 2012)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
114 people get NABI articles and Market Currents by email alert.
Get email alerts on NABI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
GlobeNewswire (Nov 8, 2012)
-
Analyst Scott Power Finds The Upside In Biotech Down UnderLife Sciences Report • Thu, Nov 8, 2012 -
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 25, 2012)
-
GlobeNewswire (Oct 17, 2012)
-
GlobeNewswire (Oct 16, 2012)
-
GlobeNewswire (Sep 24, 2012)
-
5 Stocks Trading Below Net Cash - Part VMarkus Aarnio • Mon, Aug 27, 2012 -
GlobeNewswire (Aug 9, 2012)
-
GlobeNewswire (Aug 2, 2012)
-
GlobeNewswire (Aug 2, 2012)
-
GlobeNewswire (Jul 31, 2012)
-
GlobeNewswire (Jul 19, 2012)
To learn more about Seeking Alpha Pro, click here.
-
Third Point Trims Position in Nabi BiopharmaceuticalsMarket Folly • Wed, Dec 22, 2010 -
Third Point Reduces Position in Nabi BiopharmaceuticalsMarket Folly • Wed, Mar 31, 2010
-
Chapman Capital Discloses 6.6% Stake in Nabi PharmaceuticalsLon Juricic • Tue, Jun 19, 2007 -
Nabi Biopharmaceuticals: Loeb's Third Point Boosts Stake to 11.4%Lon Juricic • Mon, May 14, 2007
-
-
Nabi Biopharmaceuticals Spars With Shareholders Over Board CompositionLon Juricic • Tue, Oct 31, 2006
-
-
Nabi Biopharm's Activist Holder Wants Chaiman OustedLon Juricic • Wed, Oct 11, 2006
-
Daniel Loeb Wants Nabi CEO's HeadLon Juricic • Wed, Sep 27, 2006
-
Daniel Loeb Lambastes Nabi Pharmaceuticals (NABI)Paul Kedrosky • Thu, Jun 15, 2006 -
Nabi Biopharmaceuticals Continues Clinical Development of StaphVax (NABI)BioBlogger • Fri, Mar 24, 2006
-
Analyst Scott Power Finds The Upside In Biotech Down UnderLife Sciences Report • Thu, Nov 8, 2012
-
5 Stocks Trading Below Net Cash - Part VMarkus Aarnio • Mon, Aug 27, 2012
-
-
-
-
-
Biotech Clinical Trials Updates: Bristol Meyers, Nabi and DynavaxRoger Newman • Wed, Jul 27, 2011 -
5 Stocks Posting Big Losses Last WeekAlex Shadunsky • Mon, Jul 25, 2011 -
5 Healthcare Stocks of Interest This WeekAlex Shadunsky • Wed, Jul 20, 2011
-
Monday Options Brief: SH, CLX, NABI & HWDInteractive Brokers • Mon, Jul 18, 2011 -
-
Thursday Options Brief: RIMM, ULBI, NABI & CXInteractive Brokers • Thu, Jun 16, 2011
-
-
-
-
-
-
-
Cramer's Lightning Round - Flirting with FLIR (3/18/10)SA Editor Miriam Metzinger • Fri, Mar 19, 2010 -
-
Nabi Biopharmaceuticals Q3 2009 Earnings Call TranscriptThu, Nov 5, 2009
-
Nabi Biopharmaceuticals Q4 2008 Earnings Call TranscriptWed, Mar 11, 2009
-
Nabi Biopharmaceuticals Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Nabi Biopharmaceuticals Q2 2008 Earnings Call TranscriptThu, Aug 7, 2008
-
Nabi Biopharmaceuticals Q1 2008 Earnings Call TranscriptTue, May 27, 2008
-
Nabi Biopharmaceuticals Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 25, 2012)
-
GlobeNewswire (Oct 17, 2012)
-
GlobeNewswire (Oct 16, 2012)
-
GlobeNewswire (Sep 24, 2012)
-
GlobeNewswire (Aug 9, 2012)
-
GlobeNewswire (Aug 2, 2012)
-
GlobeNewswire (Aug 2, 2012)
-
GlobeNewswire (Jul 31, 2012)
-
GlobeNewswire (Jul 19, 2012)
-
GlobeNewswire (Jul 2, 2012)
-
GlobeNewswire (May 10, 2012)
NABI vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the development of vaccines addressing unmet medical needs in the areas of nicotine addiction and infectious disease. We leverage our experience and knowledge in powering the human immune system to target serious unmet medical needs in these areas.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, November 6, 2012, 9:29 AM Nabi Biopharmaceuticals (NABI) declares special dividend of $1.108/share. For shareholders of record Oct. 26. Payable Nov. 8. Ex-div Nov. 9. (PR) Comment! [Dividends]
-
Monday, November 5, 2012, 9:10 AM
Premarket gainers: BMRN +28%. NTE +19%. NABI +12%. TRQ +10%. SOHU +9%. KBW +7%. ANTH +5%.
Losers: MTW -9%. RDN -9%. WYNN -6%. Comment! [On the Move] - Wednesday, October 17, 2012, 11:45 AM Xstelos Holdings has delivered a letter to Nabi Biopharmaceuticals (NABI +1.7%) expressing its belief that NABI's proposed merger with Biota Holdings undervalues the company. For this reason, Xstelos, who holds a 7..6% stake in NABI, intends to vote against the merger. The firm adds that if the deal isn't approved by stockholders, NABI should immediately return substantially all of its cash to shareholders through a dividend or other distribution. Comment! [Healthcare]
- Wednesday, October 17, 2012, 11:00 AM Nabi Biopharmaceuticals (NABI +1.1%) recovers from its pre-open dip, now trading higher despite its earlier announcement that Phase 2 studies of its smoking-cessation vaccine didn't meet the primary endpoint, creating another setback for the drug. Comment! [Healthcare, On the Move]
- Tuesday, September 18, 2012, 2:24 PM Nabi Biopharmaceutical (NABI +2.3%) and prospective merger partner Biota Holdings both agree to revise terms of their deal, providing $27M to be split among NABI shareholders to compensate for Biota's reduced share value since the transaction was announced in April. Comment! [Healthcare, M&A, On the Move]
- Wednesday, March 14, 2012, 4:22 PM Nabi Biopharmaceuticals (NABI): Q4 EPS of -$0.05 beats by $0.06. Revenue of $0.8M (-79% Y/Y). Shares +1.1% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Monday, July 18, 2011, 10:03 AM Shares of Nabi Biopharmaceuticals (NABI -69.1%) plunge after results of clinical trials for its NicVax anti-smoking treatment showed it did not beat a placebo. (PR) Comment! [On the Move, Healthcare]
- Monday, November 16, 2009, 9:22 AM GlaxoSmithKline (GSK +0.6%) and Nabi Biopharmaceuticals (NABI +30.5%) agree to work together to develop vaccines to help smokers kick the habit. Nabi to receive $40M up front, and milestone payments that could reach more than $500M. Comment!
-
Monday, November 16, 2009, 9:00 AM
Premarket gainers: NABI +33%. IBKC +23%. NLST +16%. S +8%. ABK +6%. STP +6%. SOL +6%. FRO +5%. RTP +4%. QTWW +4%. C +4%. MT +4%. HL +4%. RFMD +4%. RCL +4%. SNV +4%. MGM +4%.
Losers: TBV -22%. ADY -19%. PWRD -5%. AIB -5%. BZH -5%. TRW -4%. IRE -4%. Comment!